Fount of Information

ACROBiosystems社 Treatment of Cancer Improved by Combination Therapy Regimen





 Scientific Talk


 About Us


Treatment of Cancer Improved by Combination Therapy Regimen


The Phase 3 trial of Sanofi and Regeneron’s PD-1 inhibitor Libtayo in combination with platinum-doublet chemotherapy was stopped early after meeting its overall survival (OS) primary endpoint in patients with advanced non-small-cell lung cancer (NSCLC). Besides, A new preclinical study suggests that combining immune checkpoint inhibitors targeting PD-1/ PD-L1 with MAPK-targeted therapy—drugs typically used separately— may help overcome cancer treatment resistance.


More and more studies have shown that immune checkpoint combination therapy has a good effect in dealing with cancer.


ACROBiosystems has developed an exclusive immune checkpoint protein collection. 


Product Features


  • High purity verified by MALS or HPLC.
  • High bioactivity verified by ELISA/SPR/FACS, etc.
  • High batch to batch consistency by strict QC


Main Applications:

      Immunization and antibody screening

      Cell-based assay

      Pharmacokinetic analysis





Wonder how can these immune checkpoint proteins help your drug development?




Assay Data

The protocols are available for free!


  • Authentic structure verified by SEC-MALS


Figure 1. The purity of Human CD27 Ligand, His, Flag Tag (active trimer) (MALS verified) (Cat. No. CDL-H52Da) was more than 95% in HP-SEC, and around 55-70 kDa verified by SEC-MALS. 


  • Cell-based assay

Cell-based_assay.jpgFlow Cytometry assay shows that Human PD-1, Fc Tag, low endotoxin (Cat. No. PD1-H5257) can bind to 293 cells overexpressing human PD-L1. The concentration of PD-1 used is 1 μg/mL (Routinely tested).



Fount of Information は、新商品、新規取扱メーカーなどの情報をいち早く紹介するコンテンツです。情報発信のスピードを重視しているコンテンツのため、現時点で法規制や取り扱いを確認できていない商品、定価を設定できていない商品があります。ご要望やご照会を受けた商品について、法令整備や在庫の充実を図ります。